{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:58:03Z","timestamp":1792277883041,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10157-026-02922-w","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:52:47Z","timestamp":1784865167000},"page":"1577-1583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictions of cisplatin-induced hyponatremia in patients with malignancy: a retrospective cohort survey of all cisplatin administration in clinical practice"],"prefix":"10.1007","volume":"30","author":[{"given":"Yuki","family":"Nagashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8612-8368","authenticated-orcid":false,"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2922_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.ajkd.2011.08.029","volume":"59","author":"SM Doshi","year":"2012","unstructured":"Doshi SM, Shah P, Lei X, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012;59:222\u20138.","journal-title":"Am J Kidney Dis"},{"key":"2922_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF01788840","volume":"4","author":"T Berghmans","year":"1996","unstructured":"Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer. 1996;4:341\u201350.","journal-title":"Support Care Cancer"},{"key":"2922_CR3","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/bcp.13256","volume":"83","author":"D Shepshelovich","year":"2017","unstructured":"Shepshelovich D, Schechter A, Calvarysky B, et al. Medication-induced SIADH: distribution and characterization according to medication class. Br J Clin Pharmacol. 2017;83:1801\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"2922_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/SMJ.0b013e3181e63682","volume":"103","author":"T Hamdi","year":"2010","unstructured":"Hamdi T, Latta S, Jallad B, et al. Cisplatin-induced renal salt wasting syndrome. South Med J. 2010;103:793\u20139.","journal-title":"South Med J"},{"key":"2922_CR5","first-page":"8137078","volume":"2017","author":"PC Pham","year":"2017","unstructured":"Pham PC, Reddy P, Qaqish S, et al. Cisplatin-induced renal salt wasting requiring over 12 liters of 3% saline replacement. Case Rep Nephrol. 2017;2017:8137078.","journal-title":"Case Rep Nephrol"},{"key":"2922_CR6","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.18632\/oncotarget.23536","volume":"9","author":"Y Ezoe","year":"2018","unstructured":"Ezoe Y, Mizusawa J, Katayama H, et al. An integrated analysis of hyponatremia in cancer patients receiving platinum-based or nonplatinum-based chemotherapy in clinical trials (JCOG1405-A). Oncotarget. 2018;9:6595\u2013606.","journal-title":"Oncotarget"},{"key":"2922_CR7","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1248\/bpb.b19-00477","volume":"42","author":"S Hatakeyama","year":"2019","unstructured":"Hatakeyama S, Shida T, Yamaguchi H. Risk factors for severe hyponatremia related to cisplatin: a retrospective case-control study. Biol Pharm Bull. 2019;42:1891\u20137.","journal-title":"Biol Pharm Bull"},{"key":"2922_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/jjco\/hye085","volume":"31","author":"N Boku","year":"2001","unstructured":"Boku N, Ohtsu A, Nagashima F, et al. Retrospective study of hyponatremia in Gastric cancer patients treated with a combination chemotherapy of 5-Fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? Jpn J Clin Oncol. 2001;31:382\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"2922_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","volume":"80","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Caroen S, Oronsky A, et al. Electrolyte disorders with platinum\u2011based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017;80:895\u2013907.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2922_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10157-023-02415-0","volume":"28","author":"M Yanagita","year":"2024","unstructured":"Yanagita M, Muto S, Nishiyama H, et al. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. 2024;28:85\u2013122.","journal-title":"Clin Exp Nephrol"},{"key":"2922_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10147-019-01579-8","volume":"25","author":"Y Sugiyama","year":"2020","unstructured":"Sugiyama Y, Naiki T, Tasaki Y, et al. Prognostic significance of hyponatremia induced by systemic chemotherapy in a hospital\u2011based propensity score\u2011matched analysis. Int J Clin Oncol. 2020;25:541\u201351.","journal-title":"Int J Clin Oncol"},{"key":"2922_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","volume":"36","author":"SS Motwani","year":"2018","unstructured":"Motwani SS, McMahon GM, Humphreys BD, et al. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol. 2018;36:682\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02922-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02922-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02922-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:09:43Z","timestamp":1792012183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02922-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02922-w","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number 20-344) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}